

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal617sxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:11:59 ON 18 FEB 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:12:04 ON 18 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 FEB 2004 HIGHEST RN 651291-85-9

DICTIONARY FILE UPDATES: 17 FEB 2004 HIGHEST RN 651291-85-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> butyl hydroxytoluene

BUTYL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s butyl hydroxytoluene

1012745 BUTYL

9 BUTYLS

1012745 BUTYL

(BUTYL OR BUTYLS)

102 HYDROXYTOLUENE

L1 4 BUTYL HYDROXYTOLUENE

(BUTYL(W)HYDROXYTOLUENE)

=> d 1-4

L1 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN

RN 53126-57-1 REGISTRY

CN Oxidase, butylhydroxytoluene (9CI) (CA INDEX NAME)

OTHER NAMES:

CN BHT oxidase

CN Butylated hydroxytoluene oxidase

DR 53612-25-2

MF Unspecified

CI MAN

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN

RN 36631-28-4 REGISTRY

CN Phenol, bis(1,1-dimethylethyl)methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **2,6-Di(tert-butyl)hydroxytoluene**
MF C15 H24 O
CI IDS
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL



D1- OH

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 29759-28-2 REGISTRY
CN Phenol, (1,1-dimethylethyl)methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cresol, tert-butyl- (6CI, 7CI)
OTHER NAMES:
CN tert-Butylcresol
CN **tert-Butylhydroxytoluene**
CN tert-Butylmethylphenol
DR 36812-12-1
MF C11 H16 O
CI IDS, COM
LC STN Files: AGRICOLA, BIOSIS, CA, CAOLD, CAPLUS, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, NIOSHTIC, RTECS*, TOXCENTER, USPATFULL, VETU
(*File contains numerically searchable property data)



D1- Me

D1- OH

D1- Bu-t

67 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
67 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 128-37-0 REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-methyl- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN 2,6-Bis(1,1-dimethylethyl)-4-methylphenol
 CN 2,6-Bis(tert-butyl)-4-methylphenol
 CN 2,6-Di-tert-butyl-4-hydroxytoluene
 CN 2,6-Di-tert-butyl-4-methyl-1-hydroxybenzene
 CN 2,6-Di-tert-butyl-4-methylhydroxybenzene
 CN 2,6-Di-tert-butyl-4-methylphenol
 CN 2,6-Di-tert-butyl-p-cresol
 CN 2,6-Di-tert-butyl-p-cresol
 CN 2,6-Di-tert-butyl-p-cresole
 CN 2,6-Di-tert-butyl-p-methylphenol
 CN 2,6-Di-tert-butylcresol
 CN 2,6-Di-tert-butylmethylphenol
 CN 2,6-tert-Butyl-4-methylphenol
 CN 3,5-Di-tert-butyl-4-hydroxytoluene
 CN 4-Hydroxy-3,5-di-tert-butyltoluene
 CN 4-Methyl-2,6-bis(1,1-dimethylethyl)phenol
 CN 4-Methyl-2,6-di-tert-butylphenol
 CN Advastab 401
 CN Agidol
 CN Agidol 1
 CN Alkofen BP
 CN Antage BHT
 CN Antioxidant 264
 CN Antioxidant 29
 CN Antioxidant 30
 CN Antioxidant 4
 CN Antioxidant 4K
 CN Antioxidant DBPC
 CN Antioxidant KB
 CN Antioxidant MPJ
 CN Antioxidant T 501
 CN Antox QT
 CN AO 29
 CN AO 4
 CN AO 4K
 CN AOX 4
 CN AOX 4K
 CN BAT
 CN BHT
 CN BHT 264
 CN BHT-C
 CN Buks
 CN Butylated hydroxytoluene
 CN CAO 1
 CN CAO 3
 CN Catalin CAO 3
 CN Chemanox 11
 CN Dalpac
 CN DBPC
 CN Deenax
 CN **Dibutylhydroxytoluene**

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

FS 3D CONCORD
 DR 53571-70-3, 58500-82-6, 97123-41-6, 102962-45-8, 50641-99-1, 83047-16-9,
 42615-30-5, 50356-19-9, 52683-46-2, 290348-23-1
 MF C15 H24 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
 DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT,
 ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA,

PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2,
 USPATFULL, VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12863 REFERENCES IN FILE CA (1907 TO DATE)
 106 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 12882 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s butyl hydroxyanisole
      1012745 BUTYL
          9 BUTYLS
      1012745 BUTYL
          (BUTYL OR BUTYLS)
          35 HYDROXYANISOLE
L2      2 BUTYL HYDROXYANISOLE
          (BUTYL(W)HYDROXYANISOLE)
```

=> d 1-2

```
L2  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN  82321-68-4  REGISTRY
CN  Phenol, dibutylmethoxy- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  Dibutylhydroxyanisole
MF  C15 H24 O2
CI  IDS
LC  STN Files:  BIOSIS, CA, CAPLUS, USPAT2, USPATFULL
```




D1- O- Me

D1- OH

2 (D1- Bu-n)

14 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 25013-16-5 REGISTRY
 CN Phenol, (1,1-dimethylethyl)-4-methoxy- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenol, tert-butyl-4-methoxy- (7CI, 8CI)
 OTHER NAMES:
 CN 2(3)-tert-Butyl-4-hydroxyanisole
 CN Antioxyne B
 CN BHA
 CN BHA (antioxidant)
 CN BOA
 CN BOA (antioxidant)
 CN Butylated hydroxyanisole
 CN **Butylhydroxyanisole**
 CN E 320
 CN Embanox
 CN Protex
 CN Sustane 1F
 CN Tenox BHA
 CN tert-Butyl-4-hydroxyanisole
 CN tert-Butyl-4-methoxyphenol
 CN tert-Butyl-p-hydroxyanisole
 CN **tert-Butylhydroxyanisole**
 DR 8003-24-5, 8041-81-4, 9009-68-1, 1336-31-8, 56587-66-7, 57534-28-8,
 37349-77-2
 MF C11 H16 O2
 CI IDS, COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE,
 HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
 PDLCOM*, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL,
 VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



D1-Bu-t

3516 REFERENCES IN FILE CA (1907 TO DATE)
 35 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3519 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.86	31.07

FILE 'CAPLUS' ENTERED AT 11:15:52 ON 18 FEB 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:15:52 ON 18 FEB 2004

=> s retinoid or retinol or retinyl (w) (palmitate or propionate or acetate)
L3 39157 RETINOID OR RETINOL OR RETINYL (W) (PALMITATE OR PROPIONATE OR ACETATE)

=> s l3 and (stable or stability or stabiliz?)
L4 1977 L3 AND (STABLE OR STABILITY OR STABILIZ?)

=> s l4 and (thymol or benzakonium or pentylene (w) glycol or dehydroacetate or chlorhexidine or chloramine (w) T or iodopropynyl (w) buutylcarbanate)
L5 9 L4 AND (THYMOL OR BENZAKONIUM OR PENTYLENE (W) GLYCOL OR DEHYDRO ACETATE OR CHLORHEXIDINE OR CHLORAMINE (W) T OR IODOPROPYNYL (W) BUUTYLCARBANATE)

=> d ibib abs 1-9

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:836770 CAPLUS
DOCUMENT NUMBER: 139:341739
TITLE: Urea compositions for the treatment of skin disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086291	A2	20031023	WO 2003-US10823	20030409
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-371157P P 20020410
AB The invention is directed to compns., methods of making the compns., and methods of treating cosmetic and dermatol. disorders with a composition that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are **stable** when compared to conventional urea-containing compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and galacturonic acid 8 g was slowly added to form a mol. complex until the solution changed pH from 7.4 to 1.9. A clear solution containing the mol. complex was mixed with a hydrophilic ointment.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:696304 CAPLUS
DOCUMENT NUMBER: 139:218968
TITLE: **Stable** personal care compositions containing a **retinoid**
INVENTOR(S): Resch, Bradley Steven; Zukowski, Joseph Michael; O'Donoghue, Margaret Ann; Smith, Shane Christian
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003165546	A1	20030904	US 2002-90517	20020304
WO 2003075883	A1	20030918	WO 2003-US5924	20030227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-90517 A 20020304
AB The present invention relates to topical skin care compns. having improved **stability** containing a **retinoid** and a non-paraben preservative and being substantially free of paraben preservatives. Preferred non-paraben preservatives include phenols, phenol salts, carboxylic acids, carboxylic acid salts, quaternium ammonium compds., halogens, halogen salts, alcs., inorg. salts, heterocyclic compds., emulsifying preservatives, and mixts. thereof. The present invention also relates to methods of using such compns. to regulate the condition of skin and/or hair.

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:203502 CAPLUS
DOCUMENT NUMBER: 138:226404
TITLE: Cosmetic material containing triple-encapsulated **retinol**
INVENTOR(S): Lee, Seung Ji; Jo, Byoung Kee; Lee, Young Jin; Lee, Chun Mong
PATENT ASSIGNEE(S): Coreana Cosmetics Co., Ltd., S. Korea
SOURCE: Brit. UK Pat. Appl., 25 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2379386	A1	20030312	GB 2001-29620	20011211
US 2003118616	A1	20030626	US 2001-11081	20011207
FR 2829391	A1	20030314	FR 2001-16287	20011217
JP 2003081737	A2	20030319	JP 2002-69196	20020313

PRIORITY APPLN. INFO.: KR 2001-55103 A 20010907
AB A **stabilized** cosmetic material containing triple-encapsulated **retinol**. The **retinol** is **stabilized** firstly by addition into vesicles consisting of nonionic surface-active agent, an alkyl phosphate, cholesterol, cholesteryl ester and a polyhydric alc. The firstly **stabilized retinol** is subsequently inserted into sphingosomes consisting of lecithin, ceramide and an oily carrier. Finally the double-encapsulated **retinol** is inserted into lamellar liquid-crystal emulsifying base, thereby being triply encapsulated. The preferable nonionic surface-active agents are stearyl glucoside, glyceryl stearate, tocopheryl acetate and sorbitan stearate. Preferably, the oily carriers are paraffin or liquid paraffin, the alkyl phosphate is

selected from mono-, di-, tri- and polyoxyethylene alkylphosphate and the polyhydric alc. is glycerin. More preferably, the lamellar liquid-crystal emulsifying base comprises an anionic surface-active agent, a higher fatty alc., a higher fatty acid and ceramide. Even more preferably, the anionic surface-active agent is alkyl phosphate.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:595341 CAPLUS

DOCUMENT NUMBER: 137:159019

TITLE: Products for topical applications comprising oil bodies

INVENTOR(S): Deckers, Harm M.; Van Rooijen, Gijs; Boothe, Joseph; Goll, Janis; Moloney, Maurice M.

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 577,147.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002106337	A1	20020808	US 2001-983546	20011024
US 6599513	B2	20030729		
ZA 9804459	A	19990413	ZA 1998-4459	19980526
US 6146645	A	20001114	US 1998-84777	19980527
US 6183762	B1	20010206	US 1999-448600	19991124
US 6372234	B1	20020416	US 2000-577147	20000524

PRIORITY APPLN. INFO.:

US 1997-47753P	P	19970527
US 1997-47779P	P	19970527
US 1998-75863P	P	19980225
US 1998-75864P	P	19980225
US 1998-84777	A2	19980527
US 1999-448600	A2	19991124
US 2000-577147	A2	20000524

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatol. products. A **stabilized** oil body formulation contained Safflower oils 96.50, Keltrol CG 0.70, Arlacel-165 2.50, phytic acid 0.10, and Glydant Plus 0.20%. A low detergent active body wash formulation comprised cetyl hydroxyethyl cellulose 1.00, Miracare BT 5.00, lauramide DEA 3.00, glycerin 3.00, Na2EDTA 0.05, Polysorbate-20 0.5, Glydant Plus 0.1, lanolin alc. 1.00, petrolatum 3.00, 30% ammonium lauryl sulfate 15.0, the above **stabilized** oil bodies 25.0, and citric acid 0.89%, water and fragrance qs.

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:850724 CAPLUS

DOCUMENT NUMBER: 135:376535

TITLE: Composition for make-up or skin-care in a powdery form containing a particular binder

INVENTOR(S): Hadasch, Anke; Lemann, Patricia; Simonnet, Jean-tierry

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1155676	A2	20011121	EP 2001-401249	20010515
EP 1155676	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2808999	A1	20011123	FR 2000-6448	20000519
FR 2808999	B1	20021031		
JP 2002020236	A2	20020123	JP 2001-148415	20010517
CN 1331967	A	20020123	CN 2001-122173	20010518
US 2002041854	A1	20020411	US 2001-860567	20010521
PRIORITY APPLN. INFO.:			FR 2000-6448	A 20000519

OTHER SOURCE(S): MARPAT 135:376535

AB A make-up composition contains a powdery phase and a binding phase which a continuous aqueous phase. A binding phase contained iso-Pr myristate 1.64, castor oil 2.46, vaseline oil 12.36, liquid lanolin 1.26, water 70.95, imidazoliny urea 0.3, glycerin 5, Acylglutamate HS-11 0.03, phytantriol 2.97, vaseline 2.28, chlorphenesine 0.25, and polyoxyethylene sorbitan monopalmitate 0.5%. A cosmetic make-up contained talc 77.06, iron oxide 2.74, Nylon powder 10, titanium oxide 1, preservative 0.2, and above binding phase 9%.

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:53363 CAPLUS

DOCUMENT NUMBER: 132:113082

TITLE: Improved **stable** topical ascorbic acid compositions

INVENTOR(S): Siddiqui, Mukhtar

PATENT ASSIGNEE(S): Shaklee Corporation, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002535	A1	20000120	WO 1999-US14389	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6146664	A	20001114	US 1998-113535	19980710
CA 2336799	AA	20000120	CA 1999-2336799	19990625
AU 9948316	A1	20000201	AU 1999-48316	19990625
EP 1096922	A1	20010509	EP 1999-931905	19990625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002520267	T2	20020709	JP 2000-558796	19990625
PRIORITY APPLN. INFO.:			US 1998-113535	A 19980710
			WO 1999-US14389	W 19990625

AB An ascorbic acid composition in a nonaq. or substantially anhydrous silicone vehicle has superior **stability**. Particulate ascorbic acid is substantially insol. in the disclosed polyorganosiloxane vehicles, and the vehicle substantially excludes environmental oxygen. The ascorbic acid particles have a high degree of bioavailability and effectiveness, e.g., in topical applications to reduce wrinkles and increase collagen growth

and elasticity. Thus, an ophthalmic preparation contained dimethicone 40-99, cyclomethicone 0.0-50, stearoxytrimethylsilane 0.0-10, domethiconol 0.0-10, Polysilicone-11 (Gransil GCM 5) 0.0-40, and ascorbic acid 0.1-40%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:342278 CAPLUS
DOCUMENT NUMBER: 129:99972
TITLE: Study of combined dosage forms of β -carotene with vitamins and antimicrobial agents
AUTHOR(S): Chibulyaev, T. Kh.; Vainshtein, V. A.; Sapozhkova, S. M.
CORPORATE SOURCE: St. Peterburg. Gos. Khim.-Farm. Akad., St. Petersburg, Russia
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1998), 32(2), 34-37
CODEN: KHFZAN; ISSN: 0023-1134
PUBLISHER: Izdatel'stvo Folium
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Study of the interactions of antimicrobial agents with a series of vitamins and biostimulators revealed mutual influences on the **stability** and antimicrobial activities of these compns. A promising combination for ointments combines β -carotene with aminoglycoside antibiotics, especially gentamicin.

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:221578 CAPLUS
DOCUMENT NUMBER: 116:221578
TITLE: Ophthalmic preparations containing vitamin A
INVENTOR(S): Ushio, Kazumichi; Yoshida, Kenichi
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 473159	A1	19920304	EP 1991-114550	19910829
EP 473159	B1	19950308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05004918	A2	19930114	JP 1991-293964	19910821
JP 3256997	B2	20020218		
CA 2049822	AA	19920301	CA 1991-2049822	19910826
CA 2049822	C	20010724		
US 5185372	A	19930209	US 1991-751885	19910829
ES 2069150	T3	19950501	ES 1991-114550	19910829

PRIORITY APPLN. INFO.: JP 1990-229888 A 19900830

AB A **stable** aqueous ophthalmic preparation for the treatment of dry eye syndrome comprises vitamin A or a derivative thereof, a buffering component, a nonionic surfactant, and a chelating agent. The preparation is filled in a container made of polypropylene or polyethylene terephthalate and sealed. An ophthalmic solution (pH 5.8) contained **retinol** palmitate 50,000 IU, polysorbate-80 0.17, borax 0.01, boric acid 1.7, Na edetate 0.01 g, 10% benzalkonium chloride solution 0.05 mL, and purified water to 100 mL.

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1964:495452 CAPLUS
DOCUMENT NUMBER: 61:95452
ORIGINAL REFERENCE NO.: 61:16637g-h,16638a
TITLE: Fat-soluble vitamins and biological membranes

AUTHOR(S): Lucy, J. A.; Dingle, J. T.
CORPORATE SOURCE: Strangeways Res. Lab., Cambridge, UK
SOURCE: Nature (London, United Kingdom) (1964), 204(4954),
156-60
CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A number of isoprenoid compds., including certain vitamin E and K derivs., **stabilize** lipoprotein membranes against rapid disruption by the presence of vitamin A alc. (I). In vitro treatment of a 1:40 suspension of rabbit erythrocytes with 10-20 γ ml. of I caused indentation of cells and vacuole formation. After 15 min. at 37°, most cells were lysed. This lysis was largely prevented by 50 γ /ml. of DL- α -tocopheryl acetate (II), although the shape still changed. Disruptive action of I on erythrocytes, lysosomes, and mitochondria was temperature dependent. However, electron microscopy revealed vacuoles within cells at 8°, indicating penetration of I without hemolysis. Although II prevented hemolysis induced by I, K⁺ leaked out of the erythrocytes and hemoglobin loss was extensive. The free alc. of vitamin E inhibited hemolysis due to I, as did vitamin E succinate; vitamin E phosphate was not an inhibitor, and neither was hydroquinone. Vitamin K1, ubiquinone-30, and squalene at 10 γ /ml. all inhibited hemolysis due to I. Thyroxine was inactive. Dialuric acid (0.02%) accelerates lysis by I, and so did **chloramine-T**; both of these agents overcame the protective effect of II. Lysis by oleic acid at 30 γ ml. was inhibited by the acetate ester of vitamin E. Hypotonic release of K⁺ and hemoglobin from rabbit erythrocytes was inhibited by I, and by its Me ester and aldehyde (but not the palmitate ester).

=> d iall 8

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:221578 CAPLUS
DOCUMENT NUMBER: 116:221578
ENTRY DATE: Entered STN: 31 May 1992
TITLE: Ophthalmic preparations containing vitamin A
INVENTOR(S): Ushio, Kazumichi; Yoshida, Kenichi
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English

INT. PATENT CLASSIF.:
MAIN: A61K009-06
SECONDARY: A61K031-07; A61K031-23
CLASSIFICATION: 63-6 (Pharmaceuticals)
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 473159	A1	19920304	EP 1991-114550	19910829
EP 473159	B1	19950308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05004918	A2	19930114	JP 1991-293964	19910821
JP 3256997	B2	20020218		
CA 2049822	AA	19920301	CA 1991-2049822	19910826
CA 2049822	C	20010724		
US 5185372	A	19930209	US 1991-751885	19910829
ES 2069150	T3	19950501	ES 1991-114550	19910829
PRIORITY APPLN. INFO.:			JP 1990-229888	A 19900830

ABSTRACT:

A **stable** aqueous ophthalmic preparation for the treatment of dry eye syndrome comprises vitamin A or a derivative thereof, a buffering component, a nonionic

surfactant, and a chelating agent. The preparation is filled in a container made of polypropylene or polyethylene terephthalate and sealed. An ophthalmic solution (pH 5.8) contained **retinol** palmitate 50,000 IU, polysorbate-80 0.17, borax 0.01, boric acid 1.7, Na edetate 0.01 g, 10% benzalkonium chloride solution 0.05 mL, and purified water to 100 mL.

SUPPL. TERM: dry eye syndrome vitamin A; ophthalmic soln vitamin A buffer
INDEX TERM: Buffer substances and systems
Chelating agents
Quaternary ammonium compounds, biological studies
ROLE: BIOL (Biological study)
(ophthalmic solns. containing vitamin A and)
INDEX TERM: Quaternary ammonium compounds, biological studies
ROLE: BIOL (Biological study)
(alkylbenzyltrimethyl, chlorides, ophthalmic solns. containing
vitamin A and)
INDEX TERM: Castor oil
ROLE: BIOL (Biological study)
(hydrogenated, ethoxylated, ophthalmic solns. containing
vitamin A and)
INDEX TERM: Eye, disease
(keratoconjunctivitis sicca, treatment of, ophthalmic
solns. containing vitamin A for)
INDEX TERM: Surfactants
(nonionic, ophthalmic solns. containing vitamin A and)
INDEX TERM: Pharmaceutical dosage forms
(solns., ophthalmic, of vitamin A, buffers and chelators
in, storage **stability** improvement in)
INDEX TERM: 56-86-0, Glutamic acid, biological studies 60-32-2,
 ϵ -Aminocaproic acid 77-92-9, Citric acid,
biological studies 1303-96-4, Borax 7558-80-7, Sodium
dihydrogen phosphate 7664-38-2, Phosphoric acid,
biological studies 10043-35-3, Boric acid, biological
studies
ROLE: BIOL (Biological study)
(buffers containing, in manufacture of ophthalmic solns.)
INDEX TERM: 9003-07-0, Polypropylene 25038-59-9, Polyethylene
terephthalate, biological studies
ROLE: BIOL (Biological study)
(containers for ophthalmic solns. manufacture with)
INDEX TERM: 64-02-8, Sodium edetate 9005-65-6, Polysorbate 80
18472-51-0, **Chlorhexidine** digluconate
ROLE: BIOL (Biological study)
(ophthalmic solns. containing vitamin A and)
INDEX TERM: 68-26-8, Vitamin A 79-81-2, **Retinol** palmitate
ROLE: BIOL (Biological study)
(ophthalmic solns. containing, for dry eye syndrome
treatment)

=> diall 4-7

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:595341 CAPLUS
DOCUMENT NUMBER: 137:159019
ENTRY DATE: Entered STN: 09 Aug 2002
TITLE: Products for topical applications comprising oil
bodies
INVENTOR(S): Deckers, Harm M.; Van Rooijen, Gijs; Boothe, Joseph;
Goll, Janis; Moloney, Maurice M.
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S.
Ser. No. 577,147.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: A61K007-42
 SECONDARY: A61K007-44
 US PATENT CLASSIF.: 424059000
 CLASSIFICATION: 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 63
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002106337	A1	20020808	US 2001-983546	20011024
US 6599513	B2	20030729		
ZA 9804459	A	19990413	ZA 1998-4459	19980526
US 6146645	A	20001114	US 1998-84777	19980527
US 6183762	B1	20010206	US 1999-448600	19991124
US 6372234	B1	20020416	US 2000-577147	20000524

PRIORITY APPLN. INFO.:

US 1997-47753P	P	19970527
US 1997-47779P	P	19970527
US 1998-75863P	P	19980225
US 1998-75864P	P	19980225
US 1998-84777	A2	19980527
US 1999-448600	A2	19991124
US 2000-577147	A2	20000524

ABSTRACT:

The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatol. products. A **stabilized oil** body formulation contained Safflower oils 96.50, Keltrol CG 0.70, Arlacel-165 2.50, phytic acid 0.10, and Glydant Plus 0.20%. A low detergent active body wash formulation comprised cetyl hydroxyethyl cellulose 1.00, Miracare BT 5.00, lauramide DEA 3.00, glycerin 3.00, Na2EDTA 0.05, Polysorbate-20 0.5, Glydant Plus 0.1, lanolin alc. 1.00, petrolatum 3.00, 30% ammonium lauryl sulfate 15.0, the above **stabilized oil** bodies 25.0, and citric acid 0.89%, water and fragrance qs.

SUPPL. TERM: topical oil cosmetic skin
 INDEX TERM: Fats and Glyceridic oils, biological studies
 ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)
 (Bertholletia excelsa; products for topical applications
 comprising oil bodies)
 INDEX TERM: Fats and Glyceridic oils, biological studies
 ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)
 (Cucurbita maxima; products for topical applications
 comprising oil bodies)
 INDEX TERM: Enzymes, biological studies
 ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)
 (DNA-repairing; products for topical applications
 comprising oil bodies)
 INDEX TERM: Amides, biological studies
 ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)
 (N-(hydroxyalkyl), long-chain; products for topical
 applications comprising oil bodies)
 INDEX TERM: Surfactants
 (amphoteric; products for topical applications comprising
 oil bodies)
 INDEX TERM: Surfactants
 (anionic; products for topical applications comprising

oil bodies)

INDEX TERM: Surfactants
(cationic; products for topical applications comprising oil bodies)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(coriander seed; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(creams, wrinkle-preventing; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(creams; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(emollients; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(emulsions; products for topical applications comprising oil bodies)

INDEX TERM: Enzymes, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(exfoliating; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(face packs; products for topical applications comprising oil bodies)

INDEX TERM: Clays, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(green; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(hand creams; products for topical applications comprising oil bodies)

INDEX TERM: Vein, disease
(hemorrhoid; products for topical applications comprising oil bodies)

INDEX TERM: Peptides, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hormonal; products for topical applications comprising oil bodies)

INDEX TERM: Carboxylic acids, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hydroxy; products for topical applications comprising oil bodies)

INDEX TERM: Soaps
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(liquid; products for topical applications comprising oil bodies)

INDEX TERM: Cosmetics
(makeups; products for topical applications comprising oil bodies)

INDEX TERM: Proteins
ROLE: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(milk; products for topical applications comprising oil bodies)

INDEX TERM: Viscosity
(modifying agents; products for topical applications

comprising oil bodies)

INDEX TERM: Cosmetics
(moisturizers; products for topical applications
comprising oil bodies)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES
(Uses)
(mustard; products for topical applications comprising
oil bodies)

INDEX TERM: Surfactants
(nonionic; products for topical applications comprising
oil bodies)

INDEX TERM: Hormones, animal, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES
(Uses)
(peptide; products for topical applications comprising
oil bodies)

INDEX TERM: Fatty acids, biological studies
ROLE: COS (Cosmetic use); BIOL (Biological study); USES
(Uses)
(polyunsatd.; products for topical applications
comprising oil bodies)

INDEX TERM: Acne
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Athlete's foot
Bath preparations
Chelating agents
Dentifrices
Detergents
Eczema
Embryophyta
Fungicides
Hair
Human
Human herpesvirus
Leprosy
Lupus erythematosus
Odor and Odorous substances
Perfumes
Pigments, nonbiological
Psoriasis
Shampoos
Skin
Skin, disease
Sunscreens
Surfactants
Wart
(products for topical applications comprising oil bodies)

INDEX TERM: Acids, biological studies
Antibodies
Bases, biological studies
Bentonite, biological studies
Canola oil
Castor oil
Coconut oil
Corn oil
Corticosteroids, biological studies
Enzymes, biological studies
Esters, biological studies
Growth factors, animal
Jojoba oil
Kaolin, biological studies

Lanolin
 Linseed oil
 Lipids, biological studies
 Palm oil
 Peanut oil
 Polyoxyalkylenes, biological studies
 Polysiloxanes, biological studies
 Proteins
 Rape oil

Retinoids

Safflower oil
 Salts, biological studies
 Smectite-group minerals
 Soybean oil
 Steroids, biological studies
 Sunflower oil
 Tocopherols
 Vitamins

ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)

INDEX TERM: (products for topical applications comprising oil bodies)

Proteins

ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)

(radical scavenging; products for topical applications
 comprising oil bodies)

INDEX TERM: Skin, disease

(scabies; products for topical applications comprising
 oil bodies)

INDEX TERM: Proteins

ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)

(silk; products for topical applications comprising oil
 bodies)

INDEX TERM: Cosmetics

(skin-lightening; products for topical applications
 comprising oil bodies)

INDEX TERM: Sunscreens

(sun protection factor; products for topical applications
 comprising oil bodies)

INDEX TERM: Anesthetics

(topical; products for topical applications comprising
 oil bodies)

INDEX TERM: Skin, disease

(xerosis; products for topical applications comprising
 oil bodies)

INDEX TERM: 50-21-5, Lactic acid, biological studies 50-81-7, Vitamin
 C, biological studies 56-81-5, Glycerol, biological
 studies 58-95-7, Tocopherol acetate 68-26-8, Vitamin A
 69-72-7, Salicylic acid, biological studies 79-14-1,
 Glycolic acid, biological studies 79-81-2, **Retinyl**
palmitate 83-86-3, Phytic acid 94-13-3,
 Propylparaben 94-36-0, Benzoyl peroxide, biological
 studies 99-76-3, Methylparaben 111-90-0, Trivalin SF
 120-40-1, Lauramide DEA 123-31-9, Hydroquinone, biological
 studies 128-37-0, Butylated hydroxytoluene, biological
 studies 131-57-7, Benzophenone-3 139-33-3, Disodium EDTA
 139-96-8, TEA lauryl sulfate 150-13-0, p-Aminobenzoic acid
 151-21-3, Sodium lauryl sulfate, biological studies
 1314-13-2, Zinc oxide, biological studies 1332-37-2, Iron
 oxide, biological studies 1340-68-7, Bentone 1406-16-2,
 Vitamin D 1406-18-4, Vitamin E 2235-54-3, Ammonium
 Lauryl sulfate 2682-20-4, Neolone 3380-34-5, Triclosan
 5466-77-3, Octyl p-methoxycinnamate 7681-57-4, Sodium
 metabisulfite 8066-38-4, Phenonip 9000-07-1, Carrageenan

9000-40-2, Carob gum 9001-62-1, Lipase 9001-92-7,
 Protease 9004-34-6, Cellulose, biological studies
 9004-82-4, Sodium Lauryl ether sulfate 9005-64-5,
 Polysorbate 20 9006-65-9, Dimethicone 350 9013-79-0,
 Esterase 9033-06-1, Glucosidase 9035-73-8, Oxidase
 9037-80-3, Reductase 11138-66-2, Keltrol CG 12001-79-5,
 Vitamin K 13463-67-7, Titanium dioxide, biological studies
 18472-51-0, Chlorhexidine gluconate 25013-16-5,
 Butylated hydroxyanisole 25322-68-3, Polyethylene glycol
 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid
 36653-82-4, Cetyl alcohol 39236-46-9, Germall 115
 39464-87-4, Sclerogum 42175-36-0 55127-92-9, Vitamin Q
 55965-84-9, Kathon 67167-59-3, Polyethylene glycol
 stearate 70356-09-1, Butylmethoxydibenzoylmethane
 74565-11-0, Finsolv TN 84517-95-3, Germaben II
 84750-06-1, Arlacel 165 107282-91-7, Euxyl 100
 125018-88-4, Glydant Plus 223717-75-7 445290-06-2,
 Miracare BT

ROLE: COS (Cosmetic use); BIOL (Biological study); USES
 (Uses)

(products for topical applications comprising oil bodies)

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:850724 CAPLUS

DOCUMENT NUMBER: 135:376535

ENTRY DATE: Entered STN: 23 Nov 2001

TITLE: Composition for make-up or skin-care in a powdery form
 containing a particular binder

INVENTOR(S): Hadasch, Anke; Lemann, Patricia; Simonnet, Jean-tierry

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

INT. PATENT CLASSIF.:

MAIN: A61K007-035

CLASSIFICATION: 62-4 (Essential Oils and Cosmetics)

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1155676	A2	20011121	EP 2001-401249	20010515
EP 1155676	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2808999	A1	20011123	FR 2000-6448	20000519
FR 2808999	B1	20021031		
JP 2002020236	A2	20020123	JP 2001-148415	20010517
CN 1331967	A	20020123	CN 2001-122173	20010518
US 2002041854	A1	20020411	US 2001-860567	20010521
			FR 2000-6448	A 20000519

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:376535

ABSTRACT:

A make-up composition contains a powdery phase and a binding phase which a continuous aqueous phase. A binding phase contained iso-Pr myristate 1.64, castor oil 2.46, vaseline oil 12.36, liquid lanolin 1.26, water 70.95, imidazolinyl urea 0.3, glycerin 5, Acylglutamate HS-11 0.03, phytantriol 2.97, vaseline 2.28, chlorphenesine 0.25, and polyoxyethylene sorbitan monopalmitate 0.5%. A cosmetic make-up contained talc 77.06, iron oxide 2.74, Nylon powder 10, titanium oxide 1, preservative 0.2, and above binding phase 9%.

SUPPL. TERM: makeup cosmetic powder particle binding phase

INDEX TERM: Amino acids, biological studies

Peptides, biological studies

ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (N-acyl; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Sulfonic acids, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (alkyl derivs.; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Betaines
 Quaternary ammonium compounds, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (alkyl; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Quaternary ammonium compounds, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (alkylbenzyl dimethyl, chlorides; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Fats and Glyceridic oils, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (animal; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Cosmetics
 (antiaging; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Fats and Glyceridic oils, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (avocado; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Polyelectrolytes
 (cationic; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Polysiloxanes, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (cetyl Me, di-Me; composition for make-up or skin-care in powdery form containing particular binder)
 INDEX TERM: Aloe barbadensis
 Alopecia
 Anthraquinone dyes
 Anti-inflammatory agents
 Antibacterial agents
 Azo dyes
 Caramel (color)
 Ceramics
 Deodorants
 Dyes
 Fungicides
 Gelation agents
 Humectants
 Insecticides
 Microcapsules
 Microspheres
 Pearl
 Pigments, nonbiological
 Reducing agents
 Sequestering agents
 Stabilizing agents
 Sunscreens
 Suntanning agents
 Surfactants

containing (composition for make-up or skin-care in powdery form
 particular binder)
 INDEX TERM: Alcohols, biological studies
 Carbon black, biological studies
 Castor oil
 Corn oil
 Corticosteroids, biological studies
 Cottonseed oil
 Ethers, biological studies
 Fatty acids, biological studies
 Flavonoids
 Fluoropolymers, biological studies
 Glycerides, biological studies
 Hydrocarbon oils
 Isoalkanes
 Jojoba oil
 Kaolin, biological studies
 Lactoferrins
 Mica-group minerals, biological studies
 Olive oil
 Paraffin oils
 Peanut oil
 Peptides, biological studies
 Phosphatidic acids
 Polyamides, biological studies
 Polyesters, biological studies
 Polymers, biological studies
 Polysiloxanes, biological studies
 Polyurethanes, biological studies
 Rape oil
Retinoids
 Sapogenins
 Soaps
 Soybean oil
 Sunflower oil
 Tocopherols
 ROLE: BUU (Biological use, unclassified); BIOL (Biological
 study); USES (Uses)

(composition for make-up or skin-care in powdery form

containing particular binder)
 INDEX TERM: Amines, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological
 study); USES (Uses)

(composition for makeup or skin care in powdery form

containing particular binder)
 INDEX TERM: Cosmetics
 Hair preparations
 (conditioners; composition for make-up or skin-care in powdery
 form containing particular binder)
 INDEX TERM: Dyes
 (direct; composition for make-up or skin-care in powdery form
 containing particular binder)
 INDEX TERM: Hair preparations
 (dyes, oxidative; composition for make-up or skin-care in
 powdery form containing particular binder)
 INDEX TERM: Hair preparations
 (dyes; composition for make-up or skin-care in powdery form
 containing particular binder)
 INDEX TERM: Fatty acids, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological
 study); USES (Uses)
 (essential, glycerides; composition for make-up or skin-care

INDEX TERM: in powdery form containing particular binder)
Fatty acids, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethoxylated; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Centella asiatica
(extract, composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(eye liners; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Alcohols, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fatty; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(foundations; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Carboxylic acids, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Amino acids, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lipo; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(lipsticks; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(makeups; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(mascaras; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(mink; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Sterols
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(phyto; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Alcohols, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyhydric; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
(powders; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sesame; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(turtle; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Fats and Glyceridic oils, biological studies
 ROLE: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (vegetable; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: Cosmetics
 (wrinkle-preventing; composition for make-up or skin-care in powdery form containing particular binder)

INDEX TERM: 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin c, biological studies 52-90-4, Cysteine, biological studies 55-56-1, **Chlorhexidine** 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-88-5, Cholesterol, biological studies 58-08-2, Caffeine, biological studies 58-55-9, Theophylline, biological studies 60-18-4D, Tyrosine, derivs. 60-23-1, Cysteamine 60-33-3, Linoleic acid, biological studies 68-11-1, Thioglycolic acid, biological studies 68-26-8, **Retinol** 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 70-30-4, Hexachlorophene 79-14-1, Glycolic acid, biological studies 79-81-2, **Retinol** palmitate 81-13-0, Panthenol 91-53-2, Ethoxyquine 93-60-7, Methyl nicotinate 96-26-4, Dihydroxyacetone 107-46-0, Hexamethyldisiloxane 110-27-0, Isopropyl myristate 111-01-3, Squalane 112-80-1, Oleic acid, biological studies 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 118-00-3, Guanosine, biological studies 120-72-9D, Indole, derivs. 123-95-5, Butylstearate 124-07-2D, Caprylic acid, glycerides 125-33-7, Hexamidine 127-47-9, **Retinol** acetate 137-66-6, Ascorbyl palmitate 141-94-6, Hexetidine 142-47-2D, Monosodium glutamate, acyl derivs. 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 302-79-4, Retinoic acid 302-79-4D, Retinoic acid, derivs. 334-48-5D, Capric acid, glycerides 463-40-1, Linolenic acid 464-92-6, Asiatic acid 471-34-1, Calcium carbonate, biological studies 497-76-7, Arbutin 501-30-4, Kojic acid 515-69-5, α -Bisabolol 540-97-6 541-02-6 544-63-8, Myristic acid, biological studies 546-93-0, Magnesium carbonate 556-67-2 616-91-1, N-Acetyl cysteine 1190-73-4, N-Acetyl cysteamine 1256-86-6, Cholesteryl sulfate 1306-06-5, Hydroxyapatite 1314-13-2, Zinc oxide, biological studies 1314-23-4, Zirconium oxide, biological studies 1332-37-2, Iron oxide, biological studies 1406-18-4, Vitamin e 2197-63-9, Dicetylphosphate 2915-57-3 3380-34-5, Triclosan 4358-16-1, Cholesteryl phosphate 6640-03-5, Dimyristylphosphate 7069-42-3, **Retinol** propionate 7235-40-7, β -Carotene 7440-39-3D, Barium, salts, biological studies 7440-67-7D, Zirconium, salts, biological studies 7440-70-2D, Calcium, salts, biological studies 7631-86-9, Silica, biological studies 7787-59-9, Bismuth oxychloride 9001-92-7, Protease 9002-84-0, Polytetrafluoroethylene 9002-88-4, Polyethylene 9003-27-4, Polyisobutene 9003-53-6, Polystyrene 9004-61-9, Hyaluronic acid 9005-25-8, Starch, biological studies 9011-14-7, Polymethylmethacrylate 9016-00-6, Polydimethylsiloxane 9067-32-7, Sodium hyaluronate 10043-11-5, Boron nitride, biological studies 11042-64-1, γ -Orizanol 11103-57-4, Vitamin a 11118-57-3, Chromium oxide 11129-18-3, Cerium oxide 12240-15-2, Ferric Blue 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 16690-92-9D, Disodium glutamate, acyl derivs. 17181-54-3, β -

Glycerophosphate 19660-77-6, Chlorophyllin 20545-92-0,
Pur-cellin 22766-83-2, 2-Octyldodecyl myristate
23597-82-2, Hexyl nicotinate 24937-14-2,
Poly(β -alanine) 25513-34-2, Poly(β -alanine)
26545-51-7, Diethyl toluamide 26942-95-0, Glycerin
triisostearate 29468-20-0, Pyridinethione 29806-73-3,
2-Ethyl-hexyl palmitate 30399-84-9, Isostearic acid
31807-55-3, Isododecane 31900-57-9, Polydimethylsiloxane
34316-64-8, Hexyl laurate 34362-27-1, 2-Hexyl decyl
laurate 34513-50-3, Octyldodecanol 36653-82-4, Cetanol
37309-58-3, Polydecene 38304-91-5, Minoxidil 38517-23-6,
Acylglutamate HS-11 42131-25-9, Isononyl isononanoate
56275-01-5 57568-20-4, 2-Octyldodecyl lactate 57654-76-9
60554-19-0 60908-77-2, Isohexadecane 68890-66-4,
Octopirox 70424-62-3 70942-90-4, Glyceol 74563-64-7,
Phytantriol 78418-03-8, n-Dodecanoyl 5-salicylic acid
80208-78-2, Glycerol thioglycolate 81230-05-9,
Diisostearyl malate 108910-78-7, Magnesium ascorbyl
phosphate 120486-24-0, Diglycerin triisostearate
127278-53-9 134112-33-7, 2-Octyl decyl palmitate
145278-13-3 156218-15-4 197912-25-7 200260-57-7
374538-88-2D, derivs. 374690-63-8
ROLE: BUU (Biological use, unclassified); BIOL (Biological
study); USES (Uses)

(composition for make-up or skin-care in powdery form

containing

particular binder)

INDEX TERM: 7440-32-6, Titanium, biological studies 7440-66-6, Zinc,
biological studies

ROLE: BUU (Biological use, unclassified); BIOL (Biological
study); USES (Uses)

(nano-; composition for make-up or skin-care in powdery form
containing particular binder)

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:53363 CAPLUS

DOCUMENT NUMBER: 132:113082

ENTRY DATE: Entered STN: 23 Jan 2000

TITLE: Improved **stable** topical ascorbic acid
compositions

INVENTOR(S): Siddiqui, Mukhtar

PATENT ASSIGNEE(S): Shaklee Corporation, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

INT. PATENT CLASSIF.:

MAIN: A61K009-14

CLASSIFICATION: 63-6 (Pharmaceuticals)

Section cross-reference(s): 62

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002535	A1	20000120	WO 1999-US14389	19990625
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 6146664	A	20001114	US 1998-113535	19980710
CA 2336799	AA	20000120	CA 1999-2336799	19990625
AU 9948316	A1	20000201	AU 1999-48316	19990625
EP 1096922	A1	20010509	EP 1999-931905	19990625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002520267	T2	20020709	JP 2000-558796	19990625
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 1998-113535 A 19980710
WO 1999-US14389 W 19990625

ABSTRACT:

An ascorbic acid composition in a nonaq. or substantially anhydrous silicone vehicle has superior **stability**. Particulate ascorbic acid is substantially insol. in the disclosed polyorganosiloxane vehicles, and the vehicle substantially excludes environmental oxygen. The ascorbic acid particles have a high degree of bioavailability and effectiveness, e.g., in topical applications to reduce wrinkles and increase collagen growth and elasticity. Thus, an ophthalmic preparation contained dimethicone 40-99, cyclomethicone 0.0-50, stearoxytrimethylsilane 0.0-10, domethiconol 0.0-10, Polysilicone-11 (Gransil GCM 5) 0.0-40, and ascorbic acid 0.1-40%.

SUPPL. TERM: topical ascorbic acid silicone; cosmetic ascorbic acid
silicone; vitamin silicone topical

INDEX TERM: Skin, disease
(aging, wrinkles; **stable** topical ascorbic acid
compns.)

INDEX TERM: Tea products
(beverages, green, exts.; **stable** topical
ascorbic acid compns.)

INDEX TERM: Hair preparations
(conditioners; **stable** topical ascorbic acid
compns.)

INDEX TERM: Cyclosiloxanes
ROLE: BUU (Biological use, unclassified); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(di-Me; **stable** topical ascorbic acid compns.)

INDEX TERM: Beech (Fagus sylvatica)
Bilberry
Ginseng (Panax)
Grape
Matricaria recutita
Saxifraga stolonifera
(exts.; **stable** topical ascorbic acid compns.)

INDEX TERM: Natural products, pharmaceutical
ROLE: BUU (Biological use, unclassified); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(licorice, exts.; **stable** topical ascorbic acid
compns.)

INDEX TERM: Drug delivery systems
(ophthalmic; **stable** topical ascorbic acid
compns.)

INDEX TERM: Mulberry
Scutellaria
(root exts.; **stable** topical ascorbic acid
compns.)

INDEX TERM: Fats and Glyceridic oils, biological studies
ROLE: BUU (Biological use, unclassified); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(shark-liver oil; **stable** topical ascorbic acid
compns.)

INDEX TERM: Antioxidants
Cosmetics
Skin
(**stable** topical ascorbic acid compns.)

INDEX TERM: Coal tar
Polysiloxanes, biological studies

Silicone rubber, biological studies

Tannins

ROLE: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stable topical ascorbic acid compns.)

INDEX TERM: Drug delivery systems

(topical; stable topical ascorbic acid compns.)

INDEX TERM: 50-81-7, Ascorbic acid, biological studies

ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stable topical ascorbic acid compns.)

INDEX TERM: 50-21-5, Lactic acid, biological studies 50-23-7, Hydrocortisone 54-64-8, Thimerosal 57-13-6, Urea, biological studies 58-95-7, Tocopheryl acetate 59-02-9, α -Tocopherol 68-26-8, Vitamin A 68-26-8D, Vitamin A, esters 69-72-7, Salicylic acid, biological studies 79-81-2, Retinyl palmitate 89-83-8, Thymol 97-59-6, Allantoin 108-46-3, Resorcinol, biological studies 108-95-2, Phenol, biological studies 112-38-9, (Undecylenic Acid 123-31-9, Hydroquinone, biological studies 127-47-9, Retinyl acetate 302-79-4, Retinoic acid 1404-04-2, Neomycin 1405-20-5, Polymixin B Sulfate 1405-87-4, Bacitracin 1406-18-4, Vitamin E 2398-96-1, Tolnaftate 3380-34-5, Triclosan 7553-56-2, Iodine, biological studies 7704-34-9, Sulfur, biological studies 13463-41-7, Zinc pyrithione 18472-51-0, Chlorhexidine gluconate 18748-98-6, Stearyloxytrimethylsilane 22916-47-8, Miconazole 195868-36-1, Phenyl trimethicone 255706-30-0, Gransil GCM 5

ROLE: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stable topical ascorbic acid compns.)

INDEX TERM: 9006-65-9, Dimethicone

ROLE: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(trimethylsilylamino-; stable topical ascorbic acid compns.)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Herstein; US 5902591 A 1999 CAPLUS

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:342278 CAPLUS

DOCUMENT NUMBER: 129:99972

ENTRY DATE: Entered STN: 08 Jun 1998

TITLE: Study of combined dosage forms of β -carotene with vitamins and antimicrobial agents

AUTHOR(S): Chibulyaev, T. Kh.; Vainshtein, V. A.; Sapozhkova, S. M.

CORPORATE SOURCE: St. Peterburg. Gos. Khim.-Farm. Akad., St. Petersburg, Russia

SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1998), 32(2), 34-37

CODEN: KHFZAN; ISSN: 0023-1134

PUBLISHER: Izdatel'stvo Folium

DOCUMENT TYPE: Journal

LANGUAGE: Russian

CLASSIFICATION: 63-6 (Pharmaceuticals)

ABSTRACT:

Study of the interactions of antimicrobial agents with a series of vitamins and biostimulators revealed mutual influences on the stability and antimicrobial activities of these compns. A promising combination for

ointments combines β -carotene with aminoglycoside antibiotics, especially gentamicin.

SUPPL. TERM: antibiotic formulation **stability** vitamin carotene interaction
INDEX TERM: Drug interactions
(physicochem.; study of combined dosage forms of β -carotene with vitamins and antimicrobial agents)
INDEX TERM: Antimicrobial agents
Drug delivery systems
(study of combined dosage forms of β -carotene with vitamins and antimicrobial agents)
INDEX TERM: 50-81-7, Ascorbic acid, biological studies 56-75-7, Levomycetin 58-95-7, α -Tocopherol acetate 127-47-9, **Retinol** acetate 137-08-6, Calcium pantothenate 1405-10-3, Neomycin sulfate 1405-41-0, Gentamicin sulfate 1904-95-6, Ethazole sodium 7235-40-7, β -Carotene 18472-51-0, **Chlorhexidine** bigluconate 27942-00-3, Methyluracil
ROLE: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(study of combined dosage forms of β -carotene with vitamins and antimicrobial agents)

=> s l3 and (thymol or benzakonium or pentylene (w) glycol or dehydroacetate or chlorhexidine or chloramine (w) T or iodopropynyl (w) buutylcarbanate)
L6 45 L3 AND (THYMOL OR BENZAKONIUM OR PENTYLENE (W) GLYCOL OR DEHYDRO ACETATE OR CHLORHEXIDINE OR CHLORAMINE (W) T OR IODOPROPYNYL (W) BUUTYLCARBANATE)

=> s l6 not l5
L7 36 L6 NOT L5

=> duplicate remove l7
DUPLICATE PREFERENCE IS 'CAPLUS, MEDLINE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L7
L8 34 DUPLICATE REMOVE L7 (2 DUPLICATES REMOVED)

=> d ibib abs 1-34

L8 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:591125 CAPLUS
DOCUMENT NUMBER: 139:149632
TITLE: A process for the separation of chemical reaction mixtures via the in situ generation of ionic liquids from an auxiliary base and lewis acid reaction byproduct
INVENTOR(S): Maase, Matthias; Massonne, Klemens; Halbritter, Klaus; Noe, Ralf; Bartsch, Michael; Siegel, Wolfgang; Stegmann, Veit; Flores, Miguel; Huttenloch, Oliver; Becker, Michael
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062171	A2	20030731	WO 2003-EP545	20030121

WO 2003062171 A3 20031016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10202838 A1 20030807 DE 2002-10202838 20020124

DE 10230222 A1 20040122 DE 2002-10230222 20020704

PRIORITY APPLN. INFO.:

DE 2002-10202838 A 20020124


DE 2002-10230222 A 20020704

DE 2002-10248902 A 20021018


DE 2002-10251140 A 20021031

OTHER SOURCE(S): CASREACT 139:149632; MARPAT 139:149632


GI



I



II



III

AB A process for the separation of chemical reaction mixts. via the in situ generation of ionic liqs. from an auxiliary base I, II, III, etc. [R1, R2, R3, R4, R5 = H, alkyl, optionally substituted by O or S] and the lewis acid generated reaction byproduct is disclosed. Of note, the auxiliary base forms a salt with the acid generated during the reaction, upon heating this salt dissolves, creating two immiscible fluid phases, from which the product is separated from the reagents. For example, to a solution of

2,2-dimethyl-1-propanol (82.5 mmol) and 1-methylimidazole (82.5 mmol) at room temperature was added dropwise acetyl chloride (82.5 mmol). The mixture was

stirred at 20°C for 30 min, then at 75°C. The reaction suspension was transformed with heating into a two-phase liquid mixture. The upper layer was separated to afford 8.40 gm of 2,2-dimethyl-1-propanol acetate in 98% purity. Approx., 34-examples of the disclosed process, i.e., phosphorylation, silylation, sulfuration, etc., were provided.

L8 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:971738 CAPLUS

DOCUMENT NUMBER: 140:23273

TITLE: N-Acetyl cysteine and its topical use

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Pat. Appl. 2003 198,656.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003229141	A1	20031211	US 2003-462885	20030617
US 6159485	A	20001212	US 1999-227213	19990108
US 6524593	B1	20030225	US 2000-560901	20000428
US 2003198656	A1	20031023	US 2003-371504	20030221

PRIORITY APPLN. INFO.:

US 1999-227213	A1	19990108
US 2000-560901	A2	20000428
US 2003-371504	A2	20030221

AB Methods to alleviate or improve various cosmetic conditions and dermatol. disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors using compns. comprising N-acetyl-cysteine (isomeric or non-isomeric forms) and/or free acid, salt, lactone, amide or ester forms of N-acetyl-cysteine are described. The methods provided may also comprise application of a composition further containing various cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.

L8 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:737150 CAPLUS

DOCUMENT NUMBER: 139:250305

TITLE: Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin

INVENTOR(S): Shefer, Adi; Shefer, Samuel

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U. S. Ser. No. 91,935.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175333	A1	20030918	US 2003-376736	20030228
US 2003175328	A1	20030918	US 2002-91935	20020306

PRIORITY APPLN. INFO.:

US 2002-91935	A2	20020306
---------------	----	----------

AB The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatol., and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-sensitive, bioadhesive, film forming polymers, a water soluble oligomer, and a surfactant. The cosmetic, dermatol., and pharmaceutical active ingredients are soluble or dispersed in the matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin. For example, an antibiotic patch contained polyvinyl alc. 50, PVP 1, polysorbate 20 5, Maltrin 180 10, lactitol 5, glycerin 10, and chloramphenicol 0.55 %.

L8 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:737149 CAPLUS

DOCUMENT NUMBER: 139:250304

TITLE: Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin

INVENTOR(S): Shefer, Adi; Shefer, Shmuel David

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175328	A1	20030918	US 2002-91935	20020306
US 2003175333	A1	20030918	US 2003-376736	20030228
WO 2003075812	A1	20030918	WO 2003-US6400	20030303

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-91935 A2 20020306

AB The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatol., and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling polymeric matrix layer. The polymeric matrix layer comprises water-soluble, bioadhesive, film-forming polymers. The cosmetic, dermatol., and pharmaceutical active ingredients are soluble or dispersed in the polymeric matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin. For example a patch for acne treatment contained hydroxypropyl cellulose 96.5, α -bisabolol 1, Irgasan DP300 0.3, salicylic acid 0.2, and sorbitan monooleate 2 %.

L8 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:5236 CAPLUS
DOCUMENT NUMBER: 138:61327
TITLE: Hydrolyzed whole egg products for cosmetics and pharmaceuticals
INVENTOR(S): Marenick, Michael; Galderisi, Alyson
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003003117	A1	20030102	US 2002-39793	20020108
US 2003133989	A1	20030717	US 2002-260344	20021001

PRIORITY APPLN. INFO.: US 2001-298874P P 20010618
US 2002-39793 A1 20020108

AB The present invention provides a formulation comprising hydrolyzed whole egg, an emollient substance and a humectant substance; and provides a method of incorporating a hydrolyzed whole egg into a cosmetic, pharmaceutical and medicinal formulation wherein the hydrolyzed whole egg acts as a nutrient source and as a carrier of the active ingredients in the formulation to desired bodily targets.

L8 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:4769 CAPLUS
DOCUMENT NUMBER: 138:61071
TITLE: Topical compositions containing ethyl linoleate and triethyl citrate
INVENTOR(S): De Paoli Ambrosi, Gianfranco
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1269991	A2	20030102	EP 2002-425243	20020418

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: IT 2001-BS10046 A 20010620

AB The present invention relates to a composition for topical use, in particular aimed at skin care and at improving the aesthetic conditions of the same, characterized in that as active ingredient, it contains at least 1 of the active principles selected from Et linoleate and tri-Et citrate, which may be used both individually and in association. When used individually, Et linoleate can be contained in the composition at 1.0-20%. When used individually, tri-Et citrate can be contained at 0.50-30%. When used in association, Et linoleate and tri-Et citrate can be contained at 1.00-40% each. Thus, a formulation contained Staereth-21 2.000, stearate glyceride 3.000, Cyclomethicone 1.000, PPG stearyl ether 2.000, beeswax 2.000, stearic acid 1.500, sunflower oil 6.000, cetyl alc. 1.000, paraffin oil 4.000, wheat grass oil 1.000, and Et linoleate 7.500%, preservatives and perfumes qs and water to 100%.

L8 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:107831 CAPLUS
DOCUMENT NUMBER: 136:156517
TITLE: Dressings and bandages with semi-solid petrolatum-based coatings
INVENTOR(S): Scamilla Aledo, Maria Aparecida de Carvalho; Meizanis, James J.; De Oliveira, D'Artagnan Silva; Rangel, Fabio Eduardo Franca
PATENT ASSIGNEE(S): Brazil
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont. of U.S. Ser. No. 608,412, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002015726	A1	20020207	US 2000-752023	20001228
US 2003086963	A1	20030508	US 2002-200843	20020722
US 6599525	B2	20030729		
US 2003203015	A1	20031030	US 2003-459874	20030612

PRIORITY APPLN. INFO.:
US 2000-608412 B1 20000630
US 1998-199142 B1 19981124
US 2000-752023 A1 20001228
US 2002-200843 A3 20020722

AB The dressings of the invention comprise at least two components: (1) an absorbent substrate, having a first skin-facing surface and a second opposing surface; and (2) a discontinuous coating of a semi-solid composition

having an ointment-like feel overlying a portion of the first surface of said absorbent substrate. The absorbent substrate is useful as a passive dispenser of at least one active ingredient that may be contained therein. The discontinuous coating is essentially non-adherent to the skin and is useful as an active dispenser of at least one active ingredient that may be contained therein. In preferred embodiments the dressing of the invention contains at least one and more preferably at least two active ingredients intended to provide therapeutic benefit to the skin, such as antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antiallergics, anti-acne, anesthetics, anti-inflammatorys, hemostats, cosmetics, vitamins, vasodilators, emollients, pH regulators, antipruritics, counterirritants, antihistamines and steroids. For example, a semi-solid ointment composition was prepared containing (by weight) petrolatum 79.9%, Kraton G1702 7.0%, Kraton G1650 2.0%, Dow Corning 580 Wax (a mixture of stearoxytrimethylsilane and stearyl alc.) 10.0%, vitamin E acetate 0.1%, Aloe vera mineral oil extract 1.0%, and BHT 0.01%. The ointment was coated on the absorbent substrate made of a needle-punched nonwoven comprising 65% rayon fibers and 35% polyamide fibers coated with low-d. polyethylene on one side and pre-impregnated with benzalkonium chloride. The ointment composition was applied onto the substrate web at a coating weight of 3.96 g per linear meter. After passing through a controlled temperature chamber, the web was then wound on a spool along with a layer of interliner material composed of silicone-coated release paper.

L8 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:960589 CAPLUS
 DOCUMENT NUMBER: 138:29137
 TITLE: Polymer-based patch formulations for acne treatment
 INVENTOR(S): Buseman, Teri; Rolf, David; McWhorter, Daniel M.
 PATENT ASSIGNEE(S): LEC Tec Corporation, USA
 SOURCE: U.S., 24 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495158	B1	20021217	US 2001-766885	20010119
PRIORITY APPLN. INFO.:			US 2001-766885	20010119

AB An adhesive patch is provided wherein the patch includes a flexible backing having a front side and a back side. The patch also includes a therapeutic formulation positioned on and in at least a portion of the front side of the backing such that the therapeutic formulation is partially embedded in at least a portion of the front side of the backing. At least a portion of the backing is treated with a hydrophobic sizing agent such that the portion of the backing that is treated with the hydrophobic sizing agent has a surface energy of about 20 dynes/cm² to about 65 dynes/cm². The therapeutic formulation includes a topical acne drug, a solvent that dissolves the topical acne drug, and a pressure sensitive adhesive. Thus, a formulation contained polyacrylamide 13.0, karaya 6.0, maltodextrin 4.5, pectin 2.0, glycerin 47.0, propylene glycol 6.6, water 7.4, and adhesive 8.0, salicylic acid 0.5, and skin conditioners 5.0%.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:568077 CAPLUS
 DOCUMENT NUMBER: 137:129563
 TITLE: Antiwrinkle antiaging skin-lightening
 anti-inflammatory cosmetics
 INVENTOR(S): Ito, Hajime
 PATENT ASSIGNEE(S): Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002212052	A2	20020731	JP 2001-42566	20010115

PRIORITY APPLN. INFO.: JP 2001-42566 20010115

AB Title cosmetics contain (A) H₂O, natural water, alkaline water, and/or acidic water, (B) **pentylene glycol**, 1,3-butylene glycol, glycerin, diglycerin, ethoxydiglycol, PEG-60 hydrogenated castor oil, acrylic acid-C10-30 alkyl acrylate copolymer, vinyl acetate polymer, PCA-Na, betaine, cellulose gum, and/or Na hyaluronate as water-soluble thickeners, (C) EtOH and/or phenoxyethanol as antibacterial alcs., (D) ascorbyl phosphate, its salt, tocopherols, and/or **retinols** as antioxidative vitamins, (E) di-K glycyrrhizinate, licorice extract, allantoin, glycyrrhizinic acid, glycyrrhetinic acid, its derivs., its salts, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, guaiazulene, panthenol, its derivs., its salts, ε-aminocaproic acid, diclofenac Na, and/or tranexamic acid as anti-inflammatory agents, (F) KOH, NaOH, Al(OH)₃, Mg(OH)₂, Zn(OH)₂, Ca(OH)₂, and/or NH₄OH as alkali hydroxides, (G) citric acid, lactic acid, glycolic acid, and/or malic acid as organic acids, (H) fermented rice solns., extract of *Scutellaria baicalensis*, *Phellodendron amurense*, *Paeonia suffruticosa*, *Curcuma longa*, *Arnica montana*, *Tilia japonica*, carrot, *Poria cocos*, *Panax ginseng*, *Althaea officinalis*, aloe, *Urtica thunbergiana*, *Foeniculum vulgare*, witch hazel, *Scutellaria baicalensis*, *Phellodendron amurense*, *Hypericum erectum*, and/or rice as skin-lightening exts, and optionally (I) plant growth hormones.

L8 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:387796 CAPLUS
 DOCUMENT NUMBER: 136:374521
 TITLE: Cosmetic composition comprising a sapogenin and an antibacterial agent
 INVENTOR(S): Picard, Elisabeth
 PATENT ASSIGNEE(S): L'Oreal, Fr.
 SOURCE: Fr. Demande, 14 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2813019	A1	20020222	FR 2000-10806	20000822

PRIORITY APPLN. INFO.: FR 2000-10806 20000822

AB Cosmetic compns. comprising a sapogenin and an antibacterial agent are used for the prevention or the treatment of skin disorders such as acne and greasy skin. A cosmetic gel contained acrylate-C10-30 alkyl acrylate 0.5, hexyldecanol 10, isononyl isononanoate 10, diosgenin 0.3, salicylic acid 2.5, triethanolamine 4, glycerin 6, preservatives 0.25, and Sepigel-305 0.5%.

L8 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:169063 CAPLUS
 DOCUMENT NUMBER: 136:221531
 TITLE: Foaming cosmetic cream for the treatment of fatty skins
 INVENTOR(S): Picard-Lesboueyries, Elisabeth; Guillou, Veronique
 PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1184031	A2	20020306	EP 2001-401904	20010716
EP 1184031	A3	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2813189	A1	20020301	FR 2000-11130	20000831
FR 2813189	B1	20030228		
JP 2002145736	A2	20020522	JP 2001-256752	20010827
CN 1342452	A	20020403	CN 2001-125899	20010830
US 2002058010	A1	20020516	US 2001-941589	20010830

PRIORITY APPLN. INFO.: FR 2000-11130 A 20000831
 AB A foaming cosmetic cream for treatment of fatty skins comprise a surfactant system and antioitcs or antiseborrhea agents. A foaming cosmetic cream contained preservatives 0.4, tetrasodium EDTA 0.2, potassium hydroxide 7, glycerin 7, PEG-8 7, lauric acid 3, myristic acid 20, palmitic acid 3, stearic acid 3, glyceryl stearate 5, cocoyl glucoside 2, azelaic acid 5, and water q.s. 100%.

L8 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:31287 CAPLUS
 DOCUMENT NUMBER: 134:105670
 TITLE: Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use
 INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001932	A2	20010111	WO 2000-US16301	20000628
WO 2001001932	A3	20010517		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6335023	B1	20020101	US 2000-487228	20000119
BR 2000011640	A	20020514	BR 2000-11640	20000628
EP 1227820	A2	20020807	EP 2000-950220	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503436	T2	20030128	JP 2001-507430	20000628
US 2002028227	A1	20020307	US 2001-987023	20011113

PRIORITY APPLN. INFO.: US 1999-141264P P 19990630
 US 2000-487228 A 20000119
 WO 2000-US16301 W 20000628

OTHER SOURCE(S): MARPAT 134:105670
 AB Compns. comprising oligosaccharide aldonic acids are useful for general

care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

L8 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:194757 CAPLUS
DOCUMENT NUMBER: 134:227161
TITLE: Topical and buccal compositions containing cationic disinfectants and vitamins
INVENTOR(S): Hayashi, Kanesuzu; Takemura, Akane
PATENT ASSIGNEE(S): Sunstar, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001072561	A2	20010321	JP 1999-251675	19990906
PRIORITY APPLN. INFO.:			JP 1999-251675	19990906

AB This invention relates to buccal compns. and skin prepsns. comprising quaternary ammonium compound bactericides, nonionic surfactants, and vitamins. The compns. are effective for the prevention and treatment of skin diseases and periodontal diseases. A mouthwash contained ethanol 10, glycerin 20, ethoxylated hydrogenated castor oil 0.4, vitamin A 0.0001, flavors 0.1, Na saccharin 0.1, cetylpyridinium chloride 0.05, sodium citrate 0.05, tocopherol acetate 0.02, and distilled water q.s. to 100 %.

L8 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:279402 CAPLUS
DOCUMENT NUMBER: 134:300637
TITLE: Use of DHEA or its precursors and metabolites as skin depigmentation agents
INVENTOR(S): De, Lacharriere Oliver; Nouveau, Stephanie
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1092423	A2	20010418	EP 2000-118605	20000828
EP 1092423	A3	20010829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2799645	A1	20010420	FR 1999-12773	19991013
JP 2001131072	A2	20010515	JP 2000-303977	20001003
CA 2355357	AA	20010419	CA 2000-2355357	20001013
WO 2001026618	A2	20010419	WO 2000-FR2879	20001013
WO 2001026618	A3	20020510		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
FR 2803514 A1 20010713 FR 2000-13184 20001013
EP 1221933 A2 20020717 EP 2000-968050 20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2003511402 T2 20030325 JP 2001-529409 20001013
PRIORITY APPLN. INFO.: FR 1999-12773 A 19991013
WO 2000-FR2879 W 20001013

AB DHEA (dehydroepiandrosterone) or its precursors and metabolites as skin
depigmentation agents. A cosmetic composition contained DHEA 2, propylene
glycol isostearate 13, polyethylene glycol 5, propylene glycol 3,
pentylene glycol 3, glyceryl stearate and polyethylene
glycol stearate 5, ethoxylated sorbitan monostearate 0.5, ethoxylated
cetyl alc. 1, gelling agents 0.5, C12-15 alkyl benzoate 4, ethanol 3,
sodium hydroxide 0.12, preservatives 0.7, and water q.s. 100%.
Depigmentation activity of the composition was tested in 55-70 yr volunteers.

L8 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:790268 CAPLUS
DOCUMENT NUMBER: 133:354994
TITLE: Method of improving the aesthetic appearance of
epithelia
INVENTOR(S): Martin, Dennis M.; Traudt, Michael; Attar, Paul;
Morelli-abrams, Isabella
PATENT ASSIGNEE(S): Avon Products, Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066077	A1	20001109	WO 2000-US11529	20000428
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1173148	A1	20020123	EP 2000-928558	20000428
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		

PRIORITY APPLN. INFO.: US 1999-301570 A 19990429
WO 2000-US11529 W 20000428

AB An effective treatment method for improving the appearance of epithelia,
such as lip epithelia and vaginal epithelia is provided. According to the
present method, an effective amount of a composition containing **retinoid**,
preferably in a cosmetically acceptable carrier, is topically applied to
the vaginal or lip epithelia. The present invention also includes compns.
for practicing the method. A lip cream containing **retinol** 0.3,
acrylates copolymer 1.1, carbopol thickeners 0.9, disodium EDTA 0.2,
glycerin 5, propylene glycol 0.56, emollients 13.5, emulsifiers 8.5,
preservatives 1.4, antioxidants 0.1, triethanolamine 1, and water q.s. to
100 % was prepared

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:456837 CAPLUS
DOCUMENT NUMBER: 133:94281
TITLE: Skin care and protective compositions containing transfer agents and barrier materials
INVENTOR(S): Homola, Andrew M.; Dunton, Ronald K.; Pitts, Gary
PATENT ASSIGNEE(S): Four Star Partners, USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038617	A2	20000706	WO 1999-US30003	19991223
WO 2000038617	A3	20000921		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2356840	AA	20000706	CA 1999-2356840	19991223
EP 1139981	A2	20011010	EP 1999-968903	19991223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			US 1998-113950P P 19981224	
			US 1999-117283P P 19990126	
			WO 1999-US30003 W 19991223	

AB The present invention discloses compns. containing a one or more transfer agents and one or more barrier materials which form, upon application to a substrate, even a wet substrate or substrate immersed under water, adhesive, protective barriers. The compns. may be modified to provide an appropriate viscosity and other characteristics and may serve as a carrier for active agents.

L8 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:368164 CAPLUS
DOCUMENT NUMBER: 133:9160
TITLE: Coating useful as a dispenser of an active ingredient on dressings and bandages
INVENTOR(S): De Carvalho Scamilla Aledo, Maria Aparecida; Meizanis, James J.; Oliveira, D'Artagnan Silva; Rangel, Fabio Eduardo Franca
PATENT ASSIGNEE(S): Johnson & Johnson Consumer Companies, Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000030694	A1	20000602	WO 1999-US27552	19991119
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,			

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
 MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 BR 9915621 A 20010814 BR 1999-15621 19991119
 EP 1133325 A1 20010919 EP 1999-961733 19991119
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002530157 T2 20020917 JP 2000-583575 19991119
 ZA 2001005134 A 20020621 ZA 2001-5134 20010621
 PRIORITY APPLN. INFO.: US 1998-199142 A 19981124
 WO 1999-US27552 W 19991119

AB The dressings of the invention comprise at least two components: an
 absorbent substrate having a first skin-facing surface and a second
 opposing surface; and a discontinuous coating of a semi-solid composition
 having an ointment-like feel overlying a portion of the first surface of
 said absorbent substrate. The absorbent substrate is useful as a passive
 dispenser of at least one active ingredient that may be contained therein.
 The discontinuous coating is essentially non-adherent to the skin and is
 useful as an active dispenser of at least one active ingredient that may
 be contained therein. In preferred embodiments the dressing of the
 invention contains at least one and more preferably at least two active
 ingredients intended to provide therapeutic benefit to the skin. A
 coating composition contained petrolatum 79.9, Kraton G1702 7.0, Kraton G1650
 2.0, Dow Corning 580 wax 10.0, vitamin E acetate 0.1, aloe vera extract 1.0,
 and BHT 0.01%. The composition was applied to a web of the absorbent substrate
 for the preparation of the dressing and bandages of the invention.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:413287 CAPLUS

DOCUMENT NUMBER: 133:234187

TITLE: Complexes of Porcine Odorant Binding Protein with
 Odorant Molecules Belonging to Different Chemical
 Classes

AUTHOR(S): Vincent, Florence; Spinelli, Silvia; Ramoni, Roberto;
 Grolli, Stefano; Pelosi, Paolo; Cambillau, Christian;
 Tegoni, Mariella

CORPORATE SOURCE: Architecture et Fonction des Macromolécules
 Biologiques, URA 9039, CNRS, IFR1, Marseille, 13402,
 Fr.

SOURCE: Journal of Molecular Biology (2000), 300(1), 127-139
 CODEN: JMOBAK; ISSN: 0022-2836

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Porcine odorant binding protein (pOBP) is a monomer of 157 amino acid
 residues, purified in abundance from pig nasal mucosa. In contrast to the
 observation on lipocalins as **retinol** binding protein (RBP),
 major urinary protein (MUP) or bovine odorant binding protein (bOBP), no
 naturally occurring ligand was found in the β -barrel cavity of pOBP.
 Porcine OBP was therefore chosen as a simple model for structure/function
 studies with odorant mols. In competition expts. with tritiated pyrazine,
 the affinity of pOBP towards several odorant mols. belonging to different
 chemical classes has been found to be of the micromolar order, with a 1:1
 stoichiometry. The x-ray structures of pOBP complexed to these mols. were
 determined at resolution between 2.15 and 1.4 Å. As expected, the electron d.
 of the odorant mols. was observed into the hydrophobic β -barrel of the
 lipocalin. Inside this cavity, very few specific interactions were
 established between the odorant mol. and the amino acid side-chains, which
 did not undergo significant conformational change. The high B-factors

observed for the odorant mols. as well as the existence of alternative conformations reveal a non-specific mode of binding of the odorant mols. in the cavity. (c) 2000 Academic Press.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:262153 CAPLUS

DOCUMENT NUMBER: 130:301502

TITLE: Topical compositions for regulating the oily/shiny appearance of skin

INVENTOR(S): Biedermann, Kimberly Anne; Schubert, Harry L.; Parran, John Joseph

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918919	A2	19990422	WO 1998-US21675	19981014
WO 9918919	A3	19990422		
W: AU, CA, CN, CZ, CZ, ID, JP, KR, MX, SG				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6150403	A	20001121	US 1998-168648	19981008
CA 2308006	AA	19990422	CA 1998-2308006	19981014
AU 9910851	A1	19990503	AU 1999-10851	19981014
AU 744344	B2	20020221		
EP 1035828	A2	20000920	EP 1998-953490	19981014
EP 1035828	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003510241	T2	20030318	JP 2000-515557	19981014
AT 238765	E	20030515	AT 1998-953490	19981014
PRIORITY APPLN. INFO.:			US 1997-62088P	P 19971014
			WO 1998-US21675	W 19981014

AB The present invention relates to methods for inhibiting sebaceous gland activity in mammalian skin comprising administration of a topical composition comprising dehydroacetic acid or pharmaceutically acceptable salts thereof, and a dermatol.-acceptable carrier. The present invention also relates to methods and topical compns. further comprising agents which regulate the oily and/or shiny appearance of skin, and agents which treat acne and related skin disorders in mammalian skin and scalp. Methods of reducing sebum synthesis with the use of dehydroacetic acid, methods of regulating the oily and/or shiny appearance of skin, and methods of treating acne and other skin disorders are also encompassed by the present invention. A skin gel contained Na dehydroacetate 2, carbomer 0.65, disodium EDTA 0.1, methylparaben 0.2, glycerin 2, NaOH 0.52, phenoxyethanol 0.5, and water to 100 %.

L8 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:244554 CAPLUS

DOCUMENT NUMBER: 130:287064

TITLE: A prolamine-plant polar lipid composition, its method of preparation and applications thereof

INVENTOR(S): Fotinos, Spiros

PATENT ASSIGNEE(S): Lavipharm Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9917738	A1	19990415	WO 1998-US21014	19981002
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2317066	AA	19990415	CA 1998-2317066	19981002
AU 9897873	A1	19990427	AU 1998-97873	19981002
AU 738512	B2	20010920		
EP 1024788	A1	20000809	EP 1998-952095	19981002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 504160	A	20010831	NZ 1998-504160	19981002
US 6335388	B1	20020101	US 1998-165846	19981002
PRIORITY APPLN. INFO.:				
			US 1997-60897P	P 19971003
			WO 1998-US21014	W 19981002
AB Disclosed is a dispersion containing prolamines and polar lipids of plant origin in an hydroalcoholic solvent useful to form a skin adhesive composition for use in pharmaceutical compns. Gliadin powder 272 g and ceramide powder 2 g were added to 604 g of a hydroethanolic solution to form a dispersion, to which glycerol 33 g and sorbitol 78 g were added. The mixture was stirred to obtain a homogeneous gel. An anti-acne patch was formulated containing the above gel 89.08, anti-acne agent 10, Phenonip 0.45, K sorbate 0.05, and DL- α -tocopherol 0.42 %.				
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L8 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:799999 CAPLUS

DOCUMENT NUMBER: 130:43364

TITLE: Pyridine thiols reverse mucocutaneous aging

INVENTOR(S): Thornfeldt, Carl R.

PATENT ASSIGNEE(S): Cellergy Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9853822	A1	19981203	WO 1998-US11270	19980602
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6071543	A	20000606	US 1998-89302	19980601
AU 9877179	A1	19981230	AU 1998-77179	19980602
US 6482839	B1	20021119	US 1998-145822	19980902
PRIORITY APPLN. INFO.:				
			US 1997-47360	P 19970602
			US 1997-56282P	P 19970903
			US 1998-89302	A 19980601
			US 1997-47360P	P 19970602

US 1997-56290P P 19970903
US 1997-58752P P 19970912
WO 1998-US11270 W 19980602

AB This invention provides compns. and methods for preventing and reversing the signs and symptoms of intrinsic and photo aging. The compns. include one or more pyridine-thiols and tautomers with attached metallic moieties. Administration of the compds. to aging skin and mucous membranes in topical formulations, either as the only active ingredient or in combination with other known active ingredients, prevents and reverses aging symptoms. Addnl. compns. for preventing and reversing aging contain one or more sulfides and oxides of these same metallic ions, either alone or in combination with other mols. known or suspected to exhibit age reversing properties. Topical formulations containing both a pyridine-thiol and tautomers with attached metallic moiety and a metallic sulfide and/or metallic oxide effectively prevent and reverse the signs and symptoms of mucocutaneous aging.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:706082 CAPLUS
DOCUMENT NUMBER: 129:335760
TITLE: Molecular complex and controlled-release of α -hydroxy acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846217	A1	19981022	WO 1998-US7073	19980410
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5877212	A	19990302	US 1997-842603	19970416
AU 9868939	A1	19981111	AU 1998-68939	19980410
AU 734741	B2	20010621		
EP 1009398	A1	20000621	EP 1998-914628	19980410
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001520652	T2	20011030	JP 1998-544038	19980410
BR 9808928	A	20011204	BR 1998-8928	19980410
MX 9909504	A	20000831	MX 1999-9504	19991015

PRIORITY APPLN. INFO.: US 1997-842603 A2 19970416
WO 1998-US7073 W 19980410

AB Compns. comprising an α -hydroxy acid or related acid and organic complexing agent having a mol. weight ranging preferably between about 100 and about 600 can form a controlled-release mol. complex. Such complexing agents preferably have 1 or more amino groups in addition to other groups with unshared electrons such as OH, carbonyl, amido, ester and alkoxyl groups in the same mol. Such functional groups are capable of forming multiple intermol. hydrogen bonds with the OH groups of a free α -hydroxy acid or related acid. The complexing agents include amino acid esters, non-amphoteric amino acid amides, aminosaccharides, aminoalditols and aminocyclitols. A cream contained 7.6% glycolic acid

and 5.2% glycine Et ester in a molar ratio of 2:1. The composition reduced skin disorders like wrinkles, acne, etc.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:666024 CAPLUS

DOCUMENT NUMBER: 129:299139

TITLE: Toxicity tests in cell cultures for the purpose of predicting acute toxicity (LD50) and reducing the number of animal experiments

AUTHOR(S): Halle, Willi

CORPORATE SOURCE: Forschungszentrum Juelich G.m.b.H., Juelich, D-52425, Germany

SOURCE: Schriften des Forschungszentrums Juelich, Lebenswissenschaften/Life Sciences (1998), 1, 1-92
CODEN: SFLSF9; ISSN: 1433-5549

PUBLISHER: Forschungszentrum Juelich GmbH

DOCUMENT TYPE: Journal

LANGUAGE: German

AB An in vitro procedure for the reduction of animal expts. for toxicity tests of drugs or chems. is presented. Cytotoxicity data from in vitro cultivated mammalian cell lines were compared with acute toxicity data to predict the acute toxicity effects of xenobiotics in laboratory animals. The procedure is based on a comparison of IC50 values (IC50x) with LD50 values using linear regression anal. An enlarged registry (RC) of cytotoxicity is presented containing cytotoxicity data (IC50x) from non-selected chems. and drugs, the acute oral and i.v. LD50 values (LD50 p.o. and LD50 i.v.) from rats and mice, and the phys.-chemical characteristics of the chems. For the substances of the RC, sorted according to their IC50x-LD50 p.o. pairs, the linear regression parameters were: $r = 0.672$, intercept $a = 0.625$, and slope $b = 0.435$. For the IC50x-LD50 i.v. pairs, the same parameters were: $r = 0.768$, $a = -0.201$, and $b = 0.480$. Approx. 73% of the p.o. values and 78% of the i.v. values are localized in the LD50 dosage range around the regression lines defined by an empirical factor $FG \leq \log 5$. This percentage factor characterizes the dosage range of LD50 deviating from the regression line by the min. and maximum residuals ≤ 0.699 . The reliability of the predictive procedure was secured by using different biometrical methods and by comparisons of literature results with the data pool in the RC. The allocation of chems. into the 4 toxicity classes of acute oral toxicity defined by EU regulations (OECD Guide-line 423) resulted an accuracy of 85% in predicting the toxicity classes of the RC-substances in comparison to the toxicity classes of the corresponding NIOSH LD50 values. A comparison of RC-data with the Acute Toxic Class(ATC) method for the classification of chems. into toxicity classes resulted in a combined RC-ATC-procedure allowing the reduction of animal nos. for allocating chems. to the EU toxicity classes by 30%.

L8 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:400149 CAPLUS

DOCUMENT NUMBER: 127:23519

TITLE: Topical compositions for regulating the oily/shiny appearance of skin

INVENTOR(S): Biedermann, Kimberly Ann; Bissett, Donald Lynn; Deckner, George Endel

PATENT ASSIGNEE(S): Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9717060	A1	19970515	WO 1996-US17672	19961105
W: AU, CA, CN, CZ, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5833998	A	19981110	US 1995-554067	19951106
CA 2236918	AA	19970515	CA 1996-2236918	19961105
AU 9676061	A1	19970529	AU 1996-76061	19961105
EP 866688	A1	19980930	EP 1996-938759	19961105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 10512597	T2	19981202	JP 1996-518262	19961105
CN 1203525	A	19981230	CN 1996-198820	19961105
CN 1125633	B	20031029		
US 5980921	A	19991109	US 1998-134025	19980814
AU 738434	B2	20010920	AU 2000-34017	20000510

PRIORITY APPLN. INFO.:

US 1995-554067	A	19951106
WO 1996-US17672	W	19961105

AB The title topical compns. contain ≥ 1 of niacinamide, pyridoxine, panthenol, and pantothenic acid in a safe and effective amount combined with a cosmetically acceptable carrier. These may be combined with other active agents, e.g. anti-inflammatory agents, **retinoids**, antimicrobial agents, sunscreens, or antioxidants. Thus, a water-in-oil topical composition for use as a liquid make-up foundation contained cyclomethicone 10.25, cetyl octanoate 2.00, dimethicone copolyol 20.00, talc 3.38, pigment 10.51, Spheron L-1500 0.50, Durachem 0602 0.10, arachidyl behenate 0.30, trihydroxystearin 0.30, laureth-7 0.50, propylparaben 0.25, fragrance 0.05, water 34.44, methylparaben 0.12, propylene glycol 8.00, niacinamide 4.00, glycerin 3.00, NaCl 2.00, and Na **dehydroacetate** 0.30. Application of this foundation at 1-2 mg/cm² to the face for 4 wk resulted in a decrease in facial oil, a reduction in oily breakthrough, longer wear of the foundation, and more even coverage.

L8 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:121413 CAPLUS
DOCUMENT NUMBER: 126:135447
TITLE: Alpha hydroxyacid esters for treatment of skin aging
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): Yu, Ruey J., USA; Van Scott, Eugene J.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640047	A1	19961219	WO 1996-US8605	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
JP 3016588	B2	20000306	JP 1991-505539	19910121
US 5686489	A	19971111	US 1995-486045	19950607
AU 9660357	A1	19961230	AU 1996-60357	19960606
AU 701517	B2	19990128		
EP 831767	A1	19980401	EP 1996-917991	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
US 6051609	A	20000418	US 1998-222997	19981230
US 6191167	B1	20010220	US 1999-255702	19990223
PRIORITY APPLN. INFO.:				
US 1995-486045 A 19950607				
US 1986-945680 B2 19861223				
US 1990-467958 A 19900122				
WO 1991-US412 W 19910121				

WO 1996-US8605 W 19960606
US 1997-926030 A1 19970909
US 1997-998864 A1 19971229
US 1998-185608 A1 19981104

OTHER SOURCE(S): MARPAT 126:135447

AB Alpha hydroxyacid esters and related compds. on topical application induced increased skin thickness due to new biosynthesis of dermal components including glycosaminoglycans, proteoglycans, collagen and elastin. Such dermal effects are desirable and beneficial for topical use and treatment of aging related integumental changes including age spots, skin lines, wrinkles, photoaging and aging skin. Thus, 30 g tri-Et citrate (I) and 5 mL propylene glycol were mixed with 65 g of a hydrophilic ointment until a consistent cream was obtained. Efficacy of formulations containing I in treatment of skin disorders is disclosed.

L8 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:513433 CAPLUS
DOCUMENT NUMBER: 125:123785
TITLE: Antidandruff hair preparations
INVENTOR(S): Tsunoda, Tetsuo
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08157333	A2	19960618	JP 1994-329890	19941205
PRIORITY APPLN. INFO.:			JP 1994-329890	19941205

AB Antidandruff hair prepns. contain vitamin A (derivs.) and microbicides. A hair tonic was formulated containing **retinol**, piroctone olamine, dibutylhydroxytoluene, polyoxyethylene hydrogenated castor oil, EtOH, etc.

L8 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:660928 CAPLUS
DOCUMENT NUMBER: 125:284962
TITLE: Pharmaceutical formulations in form of thixotropic gel
INVENTOR(S): Boltri, Luigi; Coppola, Antonietta; Gentile, Marco; Clavenna, Gaetano
PATENT ASSIGNEE(S): Dompe S.P.A., Italy
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733357	A1	19960925	EP 1996-104268	19960318
EP 733357	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2171999	AA	19960923	CA 1996-2171999	19960318
US 5858330	A	19990112	US 1996-617205	19960318
AT 219930	E	20020715	AT 1996-104268	19960318
ES 2179133	T3	20030116	ES 1996-104268	19960318
JP 08325164	A2	19961210	JP 1996-105995	19960322
HK 1012566	A1	20030124	HK 1998-113936	19981217
PRIORITY APPLN. INFO.:			IT 1995-MI568	A 19950322

AB The present invention relates to a topical formulation of gel-like consistency, but nebulizable by a mech. pump, containing colloidal silica as

gellant. For example, a topical gel contained ketoprofen lysine salt 15, colloidal silica 5, propylene glycol 5, Tween 80 0.5, Na nipagin 0.1, Nerolene lavender 0.1, and demineralized water to 100 %.

L8 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:165084 CAPLUS

DOCUMENT NUMBER: 124:277873

TITLE: Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein

AUTHOR(S): Green, Mitchell D.; Tephly, Thomas R.

CORPORATE SOURCE: Dep. Pharmacol., Univ. Iowa, IA, USA

SOURCE: Drug Metabolism and Disposition (1996), 24(3), 356-63
CODEN: DMDSAI; ISSN: 0090-9556

PUBLISHER: Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Glucuronide conjugate of tertiary amine xenobiotics represents a unique and important metabolic pathway for these compds. in humans. In this study, the authors show that human UDP-glucuronosyltransferase 1.4 protein, stably expressed in human embryonic kidney 293 cells, catalyzes the N-glucuronidation of primary, secondary and tertiary amine substrates. In addition, the substrate specificity of the expressed enzyme toward many hydroxylated and carboxylic acid-containing compds. was examined. Of the hydroxylated compds. tested, only sapogenins gave glucuronidation rates comparable with those observed for amine substrates. The apparent K_M and V_{max} values for sapogenins were such that the efficiency of glucuronidation (V_{max}/K_M) for these compds. was higher than that determined for amine substrates. Human UDP-glucuronosyltransferase 1.4 also catalyzes the glucuronidation of monoterpenoid alcs. and simple phenolic compds. The enzyme kinetic values determined for these substrates suggested that this enzyme may have relatively limited significance for the conjugation of these classes of compds. Of the endobiotics tested, androstanediol and progestins were glucuronidated at high rates by expressed human UDP-glucuronosyltransferase 1.4 protein. The glucuronidation efficiency for 5 α -pregnane-3 β ,20 α -diol was comparable with that determined for the sapogenins. Because UDP-glucuronosyltransferases are integral membrane proteins, the effects of different detergents on the catalytic activity of the expressed enzyme were determined. The results show that detergents (such as Lubrol PX, Emulgen 911, and Triton X-100) are inhibitory for the quaternary ammonium-linked glucuronidation of chlorpromazine and imipramine catalyzed by expressed human UDP-glucuronosyltransferase 1.4. In contrast, CHAPS and nonanoyl-N-methylglucamide are less inhibitory toward the glucuronidation of these compds. The results suggest that human UDP-glucuronosyltransferase 1.4 may be an important enzyme for the detoxication of environmentally derived amines and sapogenins and for the conjugation of progestins.

L8 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:721434 CAPLUS

DOCUMENT NUMBER: 123:265792

TITLE: Antiacne composition comprising dispersion of lipid vesicles for the simultaneous treatment of superficial and lower layers of the skin

INVENTOR(S): Fanchon, Chantal; Ribier, Alain; Simonnet, Jean-Thierry; Segot, Evelyne

PATENT ASSIGNEE(S): Oreal S. A., Fr.

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 661036	A1	19950705	EP 1994-402895	19941215
EP 661036	B1	19960828		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
FR 2714602	A1	19950707	FR 1993-15865	19931230
FR 2714602	B1	19960209		
AT 141781	E	19960915	AT 1994-402895	19941215
ES 2094034	T3	19970101	ES 1994-402895	19941215
CA 2138873	AA	19950701	CA 1994-2138873	19941222
JP 07309781	A2	19951128	JP 1994-326411	19941227
BR 9405482	A	19950919	BR 1994-5482	19941229
HU 71722	A2	19960129	HU 1994-3821	19941229
RU 2128506	C1	19990410	RU 1994-45285	19941229
US 5679374	A	19971021	US 1994-367422	19941230

PRIORITY APPLN. INFO.:

FR 1993-15865 A 19931230

AB Antiacne compns. comprising dispersion of lipid vesicles for the simultaneous treatment of the superficial and the deep skin layers are claimed. Double liposome antiacne creams contained 33.3 g of the vesicles for the deep layer (epidermis) comprising cholesterol 8.1 triglyceryl cetyl ether 8.1, DSDHA 1.8, Me paraben 0.1, glycerin 12.0, and water q.s. 100g.; 25.0 g of the vesicles for superficial layer (stratum corneum) comprising Chimexan NS:dimyristylphosphate (95:5) 20.0, glycerin 15.0, Me paraben 0.2, salicylic acid 2.0, and water q.s. 100 g; and vegetable oil 3.0, volatile silicone 4.5, triclosan 0.2, preservatives 0.3, carboxyvinyl polymer 0.9, NaOH 1.8, and water q.s. 100 g.

L8 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:76991 CAPLUS

DOCUMENT NUMBER: 118:76991

TITLE: Preparation of astaxanthin-accumulating microorganisms for manufacture of astaxanthin-containing cells or purified carotenoid

INVENTOR(S): Villadsen, Ingrid Stampe

PATENT ASSIGNEE(S): Den.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222648	A1	19921223	WO 1992-DK186	19920615
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2111477	AA	19921223	CA 1992-2111477	19920615
AU 9219851	A1	19930112	AU 1992-19851	19920615
NO 9304613	A	19940214	NO 1993-4613	19931214


PRIORITY APPLN. INFO.:

DK 1991-1151 19910614

WO 1992-DK186 19920615

AB Astaxanthin-accumulating microorganisms are prepared by mutagenesis and selection for resistance to a phytoene dehydrogenase inhibitor and screening for colonies showing higher levels of astaxanthin coloring than control or background cells. Phaffia rhodozyma grown to late stationary phase before was treated with mutagen and astaxanthin-accumulating mutants selected. These mutants could be grown to obtain a biomass containing 1900 µg astaxanthin/g dry weight. Particularly high yields were obtained when the microbes were grown to the haploid phase before harvesting, and still higher yields were obtained by using a culture medium containing peroxisome-inducing substances.

L8 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1993:39194 CAPLUS
 DOCUMENT NUMBER: 118:39194
 TITLE: Synthesis of an iodine-125-labeled retinoid
 AUTHOR(S): Dawson, Marcia I.; Hobbs, Peter D.; Rhee, Sung W.
 CORPORATE SOURCE: SRI Int., Menlo Park, CA, 94025, USA
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals
 (1992), 31(11), 865-9
 CODEN: JLCRD4; ISSN: 0362-4803
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The carrier-free synthesis of 4-(5',6',7',8'-tetrahydro-4'-[125I]iodo-5',5',8',8'-tetramethyl-2'-anthracenyl)benzoic acid (I) is described. Site specific radioiodination was accomplished by electrophilic destannylation of the tri(n-butyl)tin analog of the retinoid with Na125I and chloramine-T. I (33 µCi, 1.65% radiochem. yield based on Na125I consumed) was purified by reversed-phase HPLC.

L8 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1991:49618 CAPLUS
 DOCUMENT NUMBER: 114:49618
 TITLE: Aqueous pharmaceutical preparations containing polyoxyethylene-polyoxypropylene and antiseptic agents
 INVENTOR(S): Fukahori, Katsuhiko; Kimura, Shigeo; Asano, Tomoaki
 PATENT ASSIGNEE(S): Zeria Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02204411	A2	19900814	JP 1989-22568	19890202
JP 2822049	B2	19981105		

PRIORITY APPLN. INFO.: JP 1989-22568 19890202

AB Aqueous pharmaceutical prepn. contain polyoxyethylene-polyoxypropylene (I) and antiseptic agents. Antiseptic effects are not decreased by I for a prolonged time. Tocopherol (0.5 g) and 2.0 g Pluronic F68 (I) were mixed with 100 mL H2O containing 0.1 mL 10% benzalkonium chloride solution and 3.0 g glucose to give an injection solution, which was inoculated with Escherichia coli and stored at 25° for 5 days to show good antiseptic activity.

L8 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 1988:197716 CAPLUS
 DOCUMENT NUMBER: 108:197716
 TITLE: Contraction of collagen lattices by skin fibroblasts: drug-induced changes
 AUTHOR(S): Adams, L. W.; Priestley, G. C.

CORPORATE SOURCE: Royal-Inf., Univ. Edinburgh, Edinburgh, EH3 9YW, UK
 SOURCE: Archives of Dermatological Research (1988), 280(2), 114-18
 CODEN: ADREDL; ISSN: 0340-3696
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A range of dermatol. useful drugs were added to human skin fibroblasts cultured in collagen lattices to assess possible effects on the rate of lattice contraction. Vitamin C, vitamin E, phenytoin, sodium salicylate, D-penicillamine and dibutyl c-AMP had no significant effect. **Chlorhexidine** acetate at 10 µg/mL arrested contraction after 24 h but this was related to its cytotoxicity. The antibiotics griseofulvin (2-16 µg/mL) and cycloheximide (5-30 µg/mL) caused dose-related inhibitions of contraction without affecting fibroblast viability. Four corticosteroids at 10 µg/mL inhibited contraction, clobetasol propionate having the greatest effect. On the other hand 4 **retinoids** at 10-5M enhanced contraction by ≤20%. As lattice contraction appears to model the contraction of skin wounds and there are broad parallels between the effects shown here of antiseptics, corticosteroids and the **retinoids**, and their reported influence on healing wounds, the lattice system may be a useful pharmacol. screen for new compds.

L8 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 1977:515914 CAPLUS
 DOCUMENT NUMBER: 87:115914
 TITLE: Discriminatory function of serum proteins in liver-bile duct diseases
 AUTHOR(S): Nilius, Ruediger; Zipprich, Bernt; Otto, Lienhard; Busse, Hans Joachim
 CORPORATE SOURCE: I Med. Klin., Martin-Luther-Univ., Halle/Saale, Ger. Dem. Rep.
 SOURCE: Zeitschrift fuer die Gesamte Innere Medizin und Ihre Grenzgebiete (1977), 32(12), 265-70
 CODEN: ZGIMAL; ISSN: 0044-2542
 DOCUMENT TYPE: Journal
 LANGUAGE: German

AB In 104 patients with acute virus hepatitis, chronic hepatitis, cirrhosis, fatty liver, and biliary diseases with partial and complete obstructive jaundice, IgG, IgA, IgD, β1A- and β1E-globulins, cholinesterase, total protein, and albumin detns. were made and in 45 of these patients **retinol**-binding protein, **thymol**-turbidity test, and electrophoretic separation of the serum were performed. Persons with a healthy liver served as controls. According to the results of univariate and multivariate variance analyses with a following test of redundancy (test for indispensability) and anal. of discriminance with calcns. of reclassification IgD, β1E-globulin, and **retinol**-binding protein were identified as not evident or redundant. The electrophoresis and **thymol** turbidity tests gave sufficient information and are recommended for orienting exams. Immune globulinogram from IgG, IgA, and IgM were suitable as mesenchyma tests. Prealbumin and cholinesterase were the most sensitive parameters of synthesis, whereas albumin and β1A-globulin had a high prognostic value.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	187.15	218.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-33.26	-33.26

STN INTERNATIONAL LOGOFF AT 11:31:37 ON 18 FEB 2004

Refine Search

Search Results -

Terms	Documents
L7 NOT L5	2

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, February 18, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=AND

<u>L8</u>	L7 NOT L5	2	<u>L8</u>
<u>L7</u>	11 AND (vitamin adj A or retinoid or retinyl or retinol or retinal)	10	<u>L7</u>
<u>L6</u>	11 NEAR (vitamin adj A or retinoid or retinyl or retinol or retinal)	0	<u>L6</u>
<u>L5</u>	L4 and (vitamin adj A or retinoid or retinyl or retinol or retinal)	8	<u>L5</u>
<u>L4</u>	o-phenylphenol and cosmetic\$	131	<u>L4</u>
<u>L3</u>	o-phenylphenol mosmetic\$	0	<u>L3</u>
<u>L2</u>	o-phenylphenol near preservative	3	<u>L2</u>
<u>L1</u>	o-phenylphenol	1089	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L7 NOT L5	2

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, February 18, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=AND

<u>L8</u>	L7 NOT L5	2	<u>L8</u>
<u>L7</u>	11 AND (vitamin adj A or retinoid or retinyl or retinol or retinal)	10	<u>L7</u>
<u>L6</u>	11 NEAR (vitamin adj A or retinoid or retinyl or retinol or retinal)	0	<u>L6</u>
<u>L5</u>	L4 and (vitamin adj A or retinoid or retinyl or retinol or retinal)	8	<u>L5</u>
<u>L4</u>	o-phenylphenol and cosmetic\$	131	<u>L4</u>
<u>L3</u>	o-phenylphenol mosmetic\$	0	<u>L3</u>
<u>L2</u>	o-phenylphenol near preservative	3	<u>L2</u>
<u>L1</u>	o-phenylphenol	1089	<u>L1</u>

END OF SEARCH HISTORY